Combination Use of Doxorubicin, Pembrolizumab Well-Tolerated in Advanced Anthracycline-Naïve SarcomaOctober 20th 2020
A phase 1/2 nonrandomized clinical trial in patients with advanced anthracycline-naïve sarcoma indicated that the treatment combination was well tolerated in this patient population.
FDA Approves Pomalidomide for Patients with AIDS-Related Kaposi SarcomaMay 15th 2020
Pomalidomide was approved for patients with AIDS-related Kaposi sarcoma whose disease has become resistant to highly active antiretroviral therapy, or in patients with Kaposi sarcoma who are HIV-negative.
Profiling of Osteosarcoma Demonstrates Why Immunotherapy is IneffectiveFebruary 25th 2020
Researchers found that poor infiltration of the tumor by immune cells, low activity from available T-cells, a lack of immune-stimulating neoantigens, and multiple immune-suppressing pathways all combine to dampen responses to immunotherapy in this disease landscape.
Location, Location, Location: Approaches to Retroperitoneal Vascular LeiomyosarcomaJanuary 15th 2020
Sarcomas are relatively rare malignant tumors that arise from mesenchymal cells and therefore encompass a variety of histologies and can occur in any anatomic compartment. The incidence of sarcoma is estimated at 1% of all new cancer diagnoses in the United States annually. Approximately 15% of soft tissue sarcomas occur in the retroperitoneum, with about 1600 new retroperitoneal sarcoma cases diagnosed in the United States each year.
A 51-Year-Old Male With Abdominal Distention, Pain, and A Retroperitoneal MassAugust 14th 2019
A 51-year-old man noticed abdominal swelling and distention with intermittent abdominal pain, early satiety, and decreased appetite over the past several months. A computed tomography scan of the abdomen is performed. What's your diagnosis?
Novel Agent Fails to Show Sufficient Activity in Recurrent OsteosarcomaNovember 14th 2017
The GPNMB-targeted agent known as glembatumumab vedotin was reasonably well tolerated and showed some activity in a phase II study of recurrent/refractory osteosarcoma, but this activity was not enough to continue the drug’s evaluation in this setting based on the study protocol.
Aftercare in Sarcoma Should Incorporate Time- and Risk-Adjusted StrategiesNovember 12th 2017
An analysis of more than 800 patients found that the one-size-fits-all approach to “aftercare” for localized soft-tissue sarcoma is misguided. Local recurrence and distant metastasis occur in a non-constant fashion in the years after treatment, and a time- and risk-adapted strategy for aftercare is warranted.
Combined Immunotherapy Shows Promise in Certain Sarcoma SubtypesNovember 10th 2017
The combination of durvalumab and tremelimumab offered a modest response rate in unselected patients with heavily pretreated metastatic sarcoma, but higher rates were seen in specific subtypes, including angiosarcoma and alveolar soft-part sarcoma.
T-Cell Therapy With Fludarabine Active in Synovial SarcomaNovember 10th 2017
NY-ESO-1 SPEAR T-cell therapy showed promising results and was reasonably safe in patients with synovial sarcoma, according to a new study. The addition of fludarabine may be important to achieving those positive results.
Uterine Sarcomas: The Latest Approaches for These Rare but Potentially Deadly TumorsMarch 15th 2017
In this review we discuss preoperative diagnosis and the role of pathology, and we summarize the current literature regarding the management of uterine sarcomas.